← Back to Search

Alpha-1 Adrenergic Receptor Antagonist

Doxazosin XL for Alcoholism

Phase 1
Waitlist Available
Led By Jin Ho Yoon, PhD
Research Sponsored by The University of Texas Health Science Center, Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Meet DSM-5 criteria for AUD;
Report excessive alcohol use as defined by CDC guidelines in the past month (>7 drinks/week for woman, >14 drinks/week for men, >3 drinks/occasion for women>4 drinks/occasion for men)3.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up friday of week 2
Awards & highlights

Study Summary

This trial will test the effects of doxazosin XL on stress and alcohol cravings in people with AUD.

Eligible Conditions
  • Alcoholism

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~friday of week 2
This trial's timeline: 3 weeks for screening, Varies for treatment, and friday of week 2 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Feasibility as study attendance
Secondary outcome measures
Alcohol Demand as assessed by the Brief Assessment of Alcohol Demand (BAAD) questionnaire
Alcohol craving as assessed by the Penn Alcohol Craving Scale (PACS)
Alcohol use as assessed by self-report
+6 more

Side effects data

From 2013 Phase 4 trial • 395 Patients • NCT01661621
10%
Dizziness
3%
General weakness
3%
Palpitation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Group 1
Group 2

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Doxazosin XLExperimental Treatment1 Intervention
Participants will receive increasing doses of doxazosin XL (0, 4, and 8 mg).
Group II: PlaceboPlacebo Group1 Intervention
Participants will be randomized to receive a placebo for doxazosin XL.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Doxazosin
FDA approved

Find a Location

Who is running the clinical trial?

The University of Texas Health Science Center, HoustonLead Sponsor
903 Previous Clinical Trials
320,977 Total Patients Enrolled
7 Trials studying Alcoholism
7,914 Patients Enrolled for Alcoholism
Jin Ho Yoon, PhDPrincipal InvestigatorThe University of Texas Health Science Center, Houston
1 Previous Clinical Trials
7 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL
Jin Ho Yoon 2022. "Targeting Stress-Induced Alcohol Relapse Risk With Doxazosin XL". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03398252.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top